- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07293520
Improving Consent Experiences in Clinical Trials
December 18, 2025 updated by: Washington University School of Medicine
Improving Consent Experiences in Clinical Trials at Siteman Cancer Center
This is a study to evaluate the impact of evidence-based visual key information (VKI) pages on participant's experiences with informed consent for research, enrollment in high-accruing studies that choose to use VKIs as part of their consent process, and research team perceptions of the implementation potential of VKIs in studies.
Unlike in previous pilots conducted at Siteman Cancer Center, this study will assess changes in outcomes before and after a VKI is implemented in a study consent process.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Mary C Politi, PhD
- Phone Number: 314-935-3802
- Email: mpoliti@wustl.edu
-
Contact:
- Eliana Goldstein
- Phone Number: 314-935-7234
- Email: goldsteinelianac@wustl.edu
-
Principal Investigator:
- Mary C Politi, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Patient Eligibility Criteria:
- Patient must be 18 years or older
- Patients must be English-speaking
- Able to understand an IRB-approved written consent document
- Must go through the consent process for one of the parent studies
Research Team Eligibility Criteria:
- Member of a parent study research team
- Engaged in the study consent processes, including creating and reviewing consents or enrolling participants
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard consent forms
The approved standard consent form will be used during the consent processes.
|
The IRB-approved consent form will be used by research team staff during consenting process of participants for parent studies.
|
|
Experimental: Standard consent forms with a visual key information (VKI) page
The approved standard consent form with a VKI page will be used during the consent processes.
|
The IRB-approved consent form will be used by research team staff during consenting process of participants for parent studies.
A VKI page will be designed for each parent study based on study materials and current consent document.
The VKI will be implemented in the consent material for the study.
|
|
Experimental: Research Team Members
Members of the parent study's research team will complete the research team survey to assess opinions on consent process.
|
The IRB-approved consent form will be used by research team staff during consenting process of participants for parent studies.
A VKI page will be designed for each parent study based on study materials and current consent document.
The VKI will be implemented in the consent material for the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient's knowledge of consent
Time Frame: Time of consent completion for parent study (day 1)
|
Knowledge of consent will be measured by patient's responses to 6-items on the patient consent experience survey.
The 6-items are customized for each parent study and have three answers for patient to choose: true, false, and unsure.
Responses will be reported via descriptive statistics and between group differences will be examined via chi-square tests.
|
Time of consent completion for parent study (day 1)
|
|
Patient's anxiety about enrolling
Time Frame: Time of consent completion for parent study (day 1)
|
Anxiety about enrolling will be captured by patient's answers to a single item on the patient consent experience survey adapted from the Amsterdam Preoperative Anxiety and Information Scale (APAIS).
The item is measured by a 5-point Likert scale as follows: Not at all, A little, Somewhat, A lot, and Extremely.
Responses be will scored as appropriate for the validated measure and between group differences will be examined via t-tests.
|
Time of consent completion for parent study (day 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient's trust in information
Time Frame: Time of consent completion for parent study (day 1)
|
Patient's trust in information will be measured by a single-item on the patient consent experience survey adapted from the Health Information National Trends Survey (HINTS) from the National Cancer Institute.
The item is a 5-point scale with answers as follows: Not at all, Slightly, Moderately, Very, and Extremely.
Responses will be scored as appropriate for the validated measure and between group differences will be examined via t-tests.
|
Time of consent completion for parent study (day 1)
|
|
Patient's perceptions of patient centered care
Time Frame: Time of consent completion for parent study (day 1)
|
Perception of patient-centered care (PCC) will be measured by three items on the patient consent experience survey which are adapted from the Health Information National Trends Survey (HINTS) from the National Cancer Institute.
The items are a 4-point scale as follows: Always, Usually, Sometimes, and Never.
Responses will be scored as appropriate for the validated measure and between group differences will be examined via t-tests.
|
Time of consent completion for parent study (day 1)
|
|
Parent study enrollment rates
Time Frame: Completion of enrollment (estimated total time is 9-13 months)
|
Enrollment rates will be measured by total number of patients enrolled in each parent study.
Responses will be reported via descriptive statistics and between group differences will be examined via t-tests.
|
Completion of enrollment (estimated total time is 9-13 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mary C Politi, PhD, Washington University in St. Louis School of Public Health
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 25, 2025
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
December 5, 2025
First Submitted That Met QC Criteria
December 5, 2025
First Posted (Estimated)
December 19, 2025
Study Record Updates
Last Update Posted (Actual)
December 26, 2025
Last Update Submitted That Met QC Criteria
December 18, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202511065
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
Palleon Pharmaceuticals, Inc.CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
Morehouse School of MedicineRecruiting
Clinical Trials on Standard Consent Form
-
National Institute of Allergy and Infectious Diseases...UnknownHIV InfectionsUnited States
-
University of California, DavisNational Center for Research Resources (NCRR)Terminated
-
Carnegie Mellon UniversityICON plcCompletedAsthma | Consent FormsUnited States
-
Mayo ClinicCompletedCancerUnited States
-
Sunnybrook Health Sciences CentreMcGill University Health Centre/Research Institute of the McGill University...RecruitingStaphylococcus Aureus BacteremiaCanada
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedImprove the Informed Consent ProcessUnited States
-
Carnegie Mellon UniversityICON plcCompletedConsent Forms
-
University of PennsylvaniaM.D. Anderson Cancer Center; Massachusetts General Hospital; Washington University... and other collaboratorsCompletedIncentives | Research EthicsUnited States
-
Taichung Veterans General HospitalUnknownSchizophrenia | CompetenceTaiwan
-
Centro Hospitalar Tondela-ViseuCompletedGastrointestinal Endoscopy | Informed ConsentPortugal